Insilico Medicine Cayman TopCo is a company principally engaged in the research and development of artificial intelligence in pharmaceuticals. The Company is engaged in the research and development of drug discovery engine. In addition, the Company is engaged in the copabdrug discovery and development of disease target identification, generation of novel molecules data, and predicting clinical trial outcomes.

Employees

-

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/03/26	65.85 $	+10.77%	5,899,904
09/03/26	59.45 $	+7.12%	6,491,500
06/03/26	55.50 $	-1.07%	3,663,301
05/03/26	56.10 $	+8.62%	2,842,650
04/03/26	51.65 $	-4.70%	3,184,500

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

2

Last Close Price

8.417USD

Average target price

9.917USD

Spread / Average Target

+17.83%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 08:08:49 10/03/2026 GMT			5-day change	1st Jan Change
65.85 ^HKD	+10.77%		+12.37%	+77.30%

03-09	InSilico Medicine Expects 2025 Losses to Widen; Shares Gain 4%	MT
03-06	Insilico Medicine Cayman Topco expects FY loss attributable of USD352.1 mln-USD355.8 mln	RE

Capitalization	4.81B 37.6B 4.13B 3.73B 3.57B 6.52B 441B 6.73B 43.94B 17.59B 212B 18.04B 17.65B 758B	P/E ratio 2025 *	-	P/E ratio 2026 *	842x
Enterprise value	4.31B 33.74B 3.7B 3.35B 3.21B 5.85B 396B 6.04B 39.43B 15.79B 190B 16.19B 15.84B 680B	EV / Sales 2025 *	78.2x	EV / Sales 2026 *	25.7x
Free-Float	-	Yield 2025 *	-	Yield 2026 *	-

03-09	InSilico Medicine Expects 2025 Losses to Widen; Shares Gain 4%	MT
03-06	Insilico Medicine Cayman Topco expects FY loss attributable of USD352.1 mln-USD355.8 mln	RE
03-06	Insilico Medicine Cayman Topco Announces First Human Enrollment and Dosing of Ism4808 in Phase I Clinical Trial	CI
03-06	InSilico Out-licensed Drug ISM4808 Begins Clinical Trial	MT
03-03	Insilico Medicine and Liquid Ai Form Strategic Partnership to Deliver Lightweight Scientific Foundation Models for Drug Discovery	CI
02-20	InSilico Medicine to Join Hang Seng Index	MT
02-10	Insilico Medicine and China Medical System Holdings Limited Enters into Strategic Partnership on Innovative Drug Development	CI
02-10	Insilico Medicine Enters Drug Development Partnership With China Medical System	MT
02-05	Insilico Medicine Nominates Ism5059, the Peripheral-Restricted Nlrp3 Inhibitor as Preclinical Candidate	CI
02-03	Insilico Medicine Receives USD 5 Million Milestone Payment from Menarini Group Following First-In-Human Achieve for Men2501	CI
02-03	Insilico Medicine Receives HK$39 Million Milestone Payment Under Licensing Deal	MT
01-27	Insilico Medicine and Qilu Pharmaceutical Group Enter into Drug Development Collaboration with Shanghai Qilu Pharmaceutical Research Center	CI
01-27	Insilico Medicine Signs AI-Driven Drug Collaboration with Qilu Pharma; Insilico Shares Up 5%	MT

03-06	Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial	PR
02-10	AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases	PR
02-05	Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications	PR
02-03	Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501	PR
01-27	Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies	PR

InSilico Medicine Cayman TopCo Share Price

Equities

3696

KYG4790P1037

Biotechnology & Medical Research

Valuation: InSilico Medicine Cayman TopCo

Chart: InSilico Medicine Cayman TopCo

Latest news: InSilico Medicine Cayman TopCo

Press Releases: InSilico Medicine Cayman TopCo

Quotes and Performance

Course Extremes

Managers and Directors: InSilico Medicine Cayman TopCo

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

1 day	+10.77%
1 week	+12.37%
Current month	+6.30%
1 month	-1.94%
Current year	+77.30%

1 week	49.9	67
1 month	49.9	80.9
Current year	35.02	80.9
1 year	29.98	80.9
3 years	29.98	80.9
5 years	29.98	80.9
10 years	29.98	80.9

Manager	Title	Age	Since
Feng Ren CEO	Chief Executive Officer	51	31/05/2022
Aleksandrs Zhavoronkov CEO	Chief Executive Officer	47	18/11/2018
Aleksandr Aliper PSD	President	-	18/11/2018

Director	Title	Age	Since
Feng Ren BRD	Director/Board Member	51	31/05/2021
Aleksandrs Zhavoronkov CHM	Chairman	47	18/11/2018
Jing Song Wang BRD	Director/Board Member	62	31/05/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
INSILICO MEDICINE CAYMAN TOPCO	+10.77%	+12.37%	-	-	4.34B
LONZA GROUP AG	-0.44%	-4.19%	-8.77%	-7.02%	44.96B
BEONE MEDICINES AG	+0.76%	+3.09%	+26.19%	+41.61%	33.54B
CELLTRION, INC.	+0.98%	-13.63%	+16.43%	+43.10%	30.24B
IQVIA HOLDINGS INC.	-3.20%	-0.35%	-8.17%	-12.12%	29.97B
REVOLUTION MEDICINES, INC.	-0.57%	-0.97%	+170.29%	+379.38%	19.78B
ASCENDIS PHARMA A/S	+0.55%	+0.75%	+74.42%	+126.92%	14.73B
MEDPACE HOLDINGS, INC.	-1.86%	+0.92%	+39.19%	+167.71%	13.58B
EUROFINS SCIENTIFIC SE	+0.22%	-3.72%	+21.86%	+0.38%	12.97B
IONIS PHARMACEUTICALS, INC.	+1.26%	-2.83%	+137.21%	+125.06%	12.45B
Average	+0.88%	-1.41%	+52.07%	+96.11%	21.65B
Weighted average by Cap.	-0.06%	-1.64%	+36.40%	+71.77%

	2025 *	2026 *
Net sales	55.18M 432M 47.38M 42.83M 41.01M 74.9M 5.07B 77.26M 504M 202M 2.43B 207M 203M 8.7B	166M 1.3B 143M 129M 123M 225M 15.26B 233M 1.52B 608M 7.31B 623M 610M 26.19B
Net income	-1.05M -8.22M -902K -815K -780K -1.43M -96.44M -1.47M -9.6M -3.84M -46.24M -3.94M -3.86M -166M	7.75M 60.63M 6.65M 6.02M 5.76M 10.52M 712M 10.85M 70.85M 28.37M 341M 29.09M 28.47M 1.22B
Net Debt	-493M -3.86B -424M -383M -367M -670M -45.31B -691M -4.51B -1.81B -21.72B -1.85B -1.81B -77.78B	-537M -4.2B -461M -417M -399M -728M -49.29B -751M -4.91B -1.96B -23.63B -2.01B -1.97B -84.6B